Burton DR, Desrosiers RC, Doms RW, et al
Burton DR, Desrosiers RC, Doms RW, et al. a large body of work providing a more complete understanding of the development of broadly neutralizing antibodies is now becoming translated into immunogen design using several different strategies. T-cell centered vaccines, fallen out of favor after Ad5-centered trials showed improved infection rates in Ad5 seropositive vaccine recipients, are going through a comeback based in part within the encouraging results from non-human primate challenge studies using rhCMV-based immunogens. This varied array of vaccine candidates may finally allow us to identify a broadly effective HIV vaccine able to contain the epidemic. 1. Intro The last ten years have seen an extraordinary acceleration in the development of at least partially effective HIV prevention modalities. Twenty years in to the use of antiretroviral therapy, the 1st randomized trial to test treatment as prevention showed a 96% reduction of HIV acquisition in the group receiving immediate treatment1,…